niacin has been researched along with Elevated Cholesterol in 241 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Excerpt | Relevance | Reference |
---|---|---|
"To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients with hypercholesterolemia and not at their low-density lipoprotein cholesterol (LDL-C) goal (as per National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C)." | 9.24 | Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. ( Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S, 2017) |
"We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia." | 9.08 | Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. ( Goldberg, AC; Guyton, JR; Kreisberg, RA; O'Connor, CM; Sprecher, DL; Superko, HR, 1998) |
"Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia." | 9.07 | Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. ( Bae, CY; Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, C; Wenz, JB, 1992) |
"Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel." | 9.07 | Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. ( Dujovne, CA; Frost, PH; Greguski, RA; Illingworth, DR; Knopp, RH; Mitchel, YB; Stein, EA; Tun, P; Zupkis, RV, 1994) |
"A double-blind, randomized study was undertaken to evaluate the efficacy and safety of fluvastatin as monotherapy and as combination therapy with niacin in the treatment of hypercholesterolemia refractory to diet." | 9.07 | Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. ( Amorosa, LF; Jacobson, TA, 1994) |
" The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations." | 8.88 | Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012) |
"All children who received single-drug niacin treatment for severe hypercholesterolemia between 1980 and 1991." | 7.68 | Niacin treatment of hypercholesterolemia in children. ( Baker, AL; Colletti, RB; McAuliffe, TL; Neufeld, EJ; Newburger, JW; Roff, NK, 1993) |
" He was receiving niacin therapy for hypercholesterolemia, and 16 hours earlier had ingested a large quantity of wine." | 7.68 | Delirium and lactic acidosis caused by ethanol and niacin coingestion. ( Bachhuber, BH; Schwab, RA, 1991) |
"Niacin treatment in hypercholesterolemic patients caused a significant increase in HDL-C and apolipoprotein A1 levels, and a decrease in triglyceride levels." | 6.78 | Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. ( Cohen, R; Hamoud, S; Hassan, A; Hayek, T; Kaplan, M; Meilin, E; Torgovicky, R, 2013) |
" Dose-response surfaces provide a practical guide for dose selection." | 6.71 | Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. ( Corbelli, J; Crouse, JR; Insull, W; McGovern, ME; Schrott, H; Thompson, P; Zieve, F, 2004) |
"Four niacin treatment groups (daily doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy." | 6.67 | Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. ( Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, CM; Wenz, JB, 1991) |
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 6.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
"To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients with hypercholesterolemia and not at their low-density lipoprotein cholesterol (LDL-C) goal (as per National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C)." | 5.24 | Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. ( Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S, 2017) |
"Reduction in xanthomata was observed with cholesterol reduction." | 5.24 | Hypercholesterolemia. Use of niacin and niacin combinations in therapy. ( RIVIN, AU, 1962) |
"An open-labeled randomized trial with parallel groups was carried out to study the effects of Dif1stat (Monascus purpureus-Linear aliphatic alcohols-Niacin) in the treatment of primary moderate hypercholesterolemia." | 5.14 | Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. ( Bucci, A; Di Giacomo, S; Mazza, F; Perrone, G; Serra, M; Stefanutti, C; Vivenzio, A, 2009) |
"We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia." | 5.08 | Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. ( Goldberg, AC; Guyton, JR; Kreisberg, RA; O'Connor, CM; Sprecher, DL; Superko, HR, 1998) |
"Low-dose niacin is a promising addition to hydroxymethylglutaryl-coenzyme A reductase inhibitor therapy in the treatment of hypercholesterolemia in patients with diabetes mellitus." | 5.08 | Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. ( Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM, 1997) |
" Six hundred and twelve patients with postdiet LDL cholesterol (LDL-C) levels in the range of 190-230 mg/dl (or 160-230 mg/dl for those with coronary heart disease or two or more coronary risk factors) were randomized to a stepped-care regimen (initial treatment with niacin followed by other agents if needed) or to initial use of lovastatin, an HMG-CoA reductase inhibitor." | 5.08 | A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). ( Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V, 1995) |
"Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia." | 5.07 | Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. ( Bae, CY; Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, C; Wenz, JB, 1992) |
"A double-blind, randomized study was undertaken to evaluate the efficacy and safety of fluvastatin as monotherapy and as combination therapy with niacin in the treatment of hypercholesterolemia refractory to diet." | 5.07 | Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. ( Amorosa, LF; Jacobson, TA, 1994) |
"Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel." | 5.07 | Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. ( Dujovne, CA; Frost, PH; Greguski, RA; Illingworth, DR; Knopp, RH; Mitchel, YB; Stein, EA; Tun, P; Zupkis, RV, 1994) |
"Noxious adverse effects frequently limit patient acceptance of niacin and bile acid sequestrants (BAS), first-line agents in the management of hypercholesterolemia." | 5.07 | Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. ( Hartz, A; Hiatt, J; Schectman, G, 1994) |
" The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations." | 4.88 | Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012) |
" Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins." | 4.81 | Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001) |
"The nonlinear dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL cholesterol-lowering effect when used together suggest a strategy for treating hypercholesterolemia that may optimize effectiveness while minimizing adverse effects and cost." | 4.79 | Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. ( Hiatt, J; Schectman, G, 1996) |
"Niacin has been used for years to treat hypercholesterolemia, but may not be as beneficial as thought for patients at high risk of cardiovascular disease." | 3.79 | Do patients on statins also need niacin? ( Jones, KW, 2013) |
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin." | 3.78 | Fluvastatin in combination with other lipid-lowering agents. ( Jokubaitis, LA, 1996) |
"To explore the effect of niacin on the serum adiponectin concentration in hypercholesterolemia rabbit and the adiponectin concentration secreted by adipocytes in normal rabbits." | 3.74 | [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits]. ( Dong, SZ; Li, J; Yang, J; Zhao, SP; Zhou, HN, 2007) |
"This study first demonstrates that in rabbits, hypercholesterolemia, both diet- or genetically induced, can influence the enzyme activities of the tryptophan-nicotinic acid pathway leading to a decreased formation of nicotinic acid, and thus NAD." | 3.72 | Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits. ( Allegri, G; Bertazzo, A; Biasiolo, M; Caparrotta, L; Comai, S; Costa, CV; Ragazzi, E, 2004) |
"All children who received single-drug niacin treatment for severe hypercholesterolemia between 1980 and 1991." | 3.68 | Niacin treatment of hypercholesterolemia in children. ( Baker, AL; Colletti, RB; McAuliffe, TL; Neufeld, EJ; Newburger, JW; Roff, NK, 1993) |
"Hepatotoxicity is a potential side effect of niacin therapy for hypercholesterolemia, ranging from mild aminotransferase elevation to fulminant hepatic failure." | 3.68 | Transient focal hepatic defects related to sustained-release niacin. ( Lawrence, SP, 1993) |
" He was receiving niacin therapy for hypercholesterolemia, and 16 hours earlier had ingested a large quantity of wine." | 3.68 | Delirium and lactic acidosis caused by ethanol and niacin coingestion. ( Bachhuber, BH; Schwab, RA, 1991) |
"Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3." | 2.79 | Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014) |
"Niacin treatment in hypercholesterolemic patients caused a significant increase in HDL-C and apolipoprotein A1 levels, and a decrease in triglyceride levels." | 2.78 | Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. ( Cohen, R; Hamoud, S; Hassan, A; Hayek, T; Kaplan, M; Meilin, E; Torgovicky, R, 2013) |
" Treatment-related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs." | 2.75 | Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. ( Ceska, R; Giezek, H; Gil-Extremera, B; Maccubbin, D; Mao, A; McCrary Sisk, C; Paolini, JF; Shah, S; Vandormael, K, 2010) |
" These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin." | 2.74 | Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. ( Chao, A; Cote, J; Dishy, V; Gutierrez, M; Lai, E; Larson, P; Laterza, O; Lauring, B; Luo, WL; Patterson, J; Wagner, JA, 2009) |
"Niacin has complementary lipid-modifying efficacy to statins and cardiovascular benefit, but is underutilised because of flushing, mediated primarily by prostaglandin D(2) (PGD(2))." | 2.73 | Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. ( Bays, HE; Betteridge, A; Elinoff, V; Elis, A; Kuznetsova, O; Maccubbin, D; Mitchel, Y; Olsson, AG; Paolini, JF; Pasternak, RC; Reyes, R; Sirah, W; Sisk, CM; Yu, Q, 2008) |
" In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated." | 2.73 | Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). ( Bajorunas, DR; Ballantyne, CM; Davidson, MH; Karas, RH; Keller, LH; McKenney, J, 2008) |
"Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD)." | 2.72 | Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes? ( Smith, SC; Stouffer, GA; Zhou, R, 2021) |
"We planned to carry out a pilot study to evaluate the efficacy and safety as an antihypercholesterolemic agent of a brand dietary supplement made of Monascus purpureus titrated extract, octacosanols and niacin on 111 Caucasian patients with low cardiovascular disease risk (<20% by Framingham algorithms), comparing them with the antihypercholesterolemic effect of a low dosage of Pravastatin on 20 subjects with similar risk profile." | 2.71 | Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. ( Brancaleoni, M; Cicero, AF; Donati, F; Laghi, L; Mino, M, 2005) |
" Dose-response surfaces provide a practical guide for dose selection." | 2.71 | Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. ( Corbelli, J; Crouse, JR; Insull, W; McGovern, ME; Schrott, H; Thompson, P; Zieve, F, 2004) |
"Niacin is a useful lipid-modifying drug because it (1) decreases low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and lipoprotein(a), and (2) raises high-density lipoprotein (HDL) cholesterol." | 2.69 | Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. ( Goldberg, AC, 1998) |
" The four groups of ten subjects received either placebo bid, chromium polynicotinate (Cr) 200 microg bid, grape seed extract (GSE) 100 mg bid, or a combination of Cr and GSE at the same dosage bid." | 2.69 | Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. ( Bagchi, D; Bui, M; Echard, B; Myers, A; Preuss, HG; Talpur, N; Tutuncuoglu, SO; Wallerstedt, D, 2000) |
" Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing." | 2.67 | Pharmacokinetics of fluvastatin and specific drug interactions. ( Hwang, DS; Jokubaitis, LA; Robinson, WT; Smith, HT; Troendle, AJ, 1993) |
"To compare escalating doses of immediate-release (IR) and sustained-release (SR) niacin for effectiveness in reducing levels of low-density lipoprotein cholesterol and triglycerides and increasing levels of high-density lipoprotein cholesterol, and for the occurrence of adverse reactions, especially hepatotoxicity." | 2.67 | A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. ( Chinchili, VM; Harris, S; McKenney, JM; Proctor, JD, 1994) |
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin." | 2.67 | Fluvastatin in combination with other lipid-lowering agents. ( Jokubaitis, LA, 1994) |
"Four niacin treatment groups (daily doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy." | 2.67 | Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. ( Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, CM; Wenz, JB, 1991) |
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)." | 2.61 | New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019) |
" There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9." | 2.55 | Lipid Lowering Therapy and Circulating PCSK9 Concentration. ( Nozue, T, 2017) |
"Niacin therapy was associated with a RR of 1." | 2.53 | Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. ( Goldie, C; McCoy, C; Nguyen, P; Preiss, D; Taylor, AJ; Zhao, XQ, 2016) |
"Hypercholesterolemia is one of the main factors in the development of atherosclerotic cardiovascular disease." | 2.47 | The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. ( Markel, A, 2011) |
"Moreover, when hypercholesterolemia is associated with low concentrations of high-density lipoprotein (HDL)-cholesterol and high triglyceride levels, the association of statins with nicotinic acid, fibrates or omega-3 should be considered." | 2.46 | [Advances in cholesterol-lowering interventions]. ( Ascaso, JF, 2010) |
" Many clinical trials have been designed to evaluate pharmacologic compounds in the treatment of the dyslipidemias and they seem to have shown a safe profile, both in the experiment phases and in post-marketing observation studies." | 2.42 | Hepatotoxicity of hypolipidemic drugs. ( Parra, JL; Reddy, KR, 2003) |
"There is clear evidence that treating hypercholesterolemia reduces cardiovascular risk in women, as well as in men." | 2.41 | Management of hypercholesterolaemia in postmenopausal women. ( Davidson, MH; Ingram, KA; Karp, SK; Maki, KC, 2002) |
" A myriad of studies that have examined efficacy, safety, adverse effects, and pharmacologic properties of niacin rendered convincing evidence that niacin, used alone or combined with other agents, has favorable effects on serum lipoprotein regulation and on containment of atherothrombotic cardiovascular diseases." | 2.41 | Niacin dosing: relationship to benefits and adverse effects. ( Brusco, OA; Capuzzi, DM; Intenzo, CM; Morgan, JM, 2000) |
"Advances in treatment of elevated cholesterol levels and recent documentation of efficacy and safety in clinical trials justify expanded use of cholesterol-lowering therapy in clinical practice." | 2.40 | Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. ( Grundy, SM, 1997) |
"Lovastatin (20 mg/d) was also efficient ($177 per percent reduction)." | 2.38 | Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. ( Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK, 1990) |
"The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed." | 2.36 | Treatment of hypercholesterolemia. ( Kane, JP; Malloy, MJ, 1982) |
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 2.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
"Ezetimibe is a lipid lowering medication that is able to inhibit dietary cholesterol." | 1.36 | Ezetimibe and recent clinical trials: a look on the bright side. ( Ahmed, MH, 2010) |
" Aspirin was used by one third of patients before Niaspan dosing to minimize flushing episodes." | 1.30 | Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. ( Brody, J; Brusco, OA; Capuzzi, DM; Goldberg, AC; Guyton, JR; Kreisberg, RA; Morgan, JM, 1998) |
"Would the money spent on treating hypercholesterolemia save more lives if spent elsewhere? How many dollars must be spent on a treatment to make one person live 1 year longer? This cost-effectiveness analysis uses the cost per year of life gained to compare a wide variety of health care interventions ranging from carcinogen research to screening tests to liver transplants." | 1.28 | Hypercholesterolemia: the cost of treatment in perspective. ( Kelley, MD, 1990) |
"lovastatin therapy to lower plasma cholesterol does not lead to corresponding reductions in body cholesterol pools or to a reduction in the rate of whole-body cholesterol synthesis." | 1.28 | Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. ( Adams, M; Dell, RB; Goldberg, IJ; Goodman, DS; Holleran, S; Palmer, RH; Ramakrishnan, R, 1990) |
"There are indications that treatment of hypercholesterolemia by means of drugs reduce risk of atherosclerosis in patients with increased concentrations of atherogenic lipoproteins." | 1.28 | [Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]. ( Blomhoff, JP; Ose, L; Torsvik, H, 1989) |
" Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual." | 1.27 | Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987) |
"Prophylactic treatment of the hyperlipoproteinemia with the drugs niceritrol (Perycit) and beta-pyridylcarbinol (Ronicol) significantly reduced the elevated plasma cholesterol level and reduced the degree of atherosclerosis in the abdominal aorta and the coronary arteries." | 1.27 | [Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs]. ( Jacobsson, L, 1986) |
"Only lovastatin treatment was free of adverse effects." | 1.27 | Comparison of six pharmacologic regimens for hypercholesterolemia. ( Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB, 1987) |
"Reduction in xanthomata was observed with cholesterol reduction." | 1.24 | Hypercholesterolemia. Use of niacin and niacin combinations in therapy. ( RIVIN, AU, 1962) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 92 (38.17) | 18.7374 |
1990's | 64 (26.56) | 18.2507 |
2000's | 43 (17.84) | 29.6817 |
2010's | 41 (17.01) | 24.3611 |
2020's | 1 (0.41) | 2.80 |
Authors | Studies |
---|---|
Fenton, G | 1 |
Newton, CG | 1 |
Wyman, BM | 1 |
Bagge, P | 1 |
Dron, DI | 1 |
Riddell, D | 1 |
Jones, GD | 1 |
Zhou, R | 1 |
Stouffer, GA | 1 |
Smith, SC | 1 |
Nozue, T | 1 |
Preston Mason, R | 1 |
Ruscica, M | 1 |
Pavanello, C | 1 |
Gandini, S | 1 |
Macchi, C | 1 |
Botta, M | 1 |
Dall'Orto, D | 1 |
Del Puppo, M | 1 |
Bertolotti, M | 1 |
Bosisio, R | 1 |
Mombelli, G | 1 |
Sirtori, CR | 1 |
Calabresi, L | 1 |
Magni, P | 1 |
Jones, KW | 1 |
Wahawisan, J | 1 |
Tovar, JM | 1 |
Granberry, MC | 2 |
Gudzune, KA | 1 |
Monroe, AK | 1 |
Sharma, R | 1 |
Ranasinghe, PD | 1 |
Chelladurai, Y | 1 |
Robinson, KA | 1 |
Lloyd-Jones, DM | 1 |
Landray, MJ | 2 |
Haynes, R | 3 |
Hopewell, JC | 1 |
Parish, S | 1 |
Aung, T | 1 |
Tomson, J | 1 |
Wallendszus, K | 1 |
Craig, M | 1 |
Jiang, L | 1 |
Collins, R | 1 |
Armitage, J | 2 |
Huynh, K | 1 |
Rembold, CM | 1 |
Meneses, F | 1 |
Hu, M | 1 |
Tomlinson, B | 1 |
van den Oever, IA | 1 |
Nurmohamed, MT | 1 |
Lems, WF | 1 |
Santos-Gallego, CG | 1 |
Badimon, J | 1 |
Mayer, L | 1 |
Bloomfield, HE | 1 |
Goldie, C | 1 |
Taylor, AJ | 1 |
Nguyen, P | 1 |
McCoy, C | 1 |
Zhao, XQ | 2 |
Preiss, D | 1 |
Rahimi, K | 1 |
Grammer, T | 1 |
Kleber, M | 1 |
Silbernagel, G | 1 |
Scharnagl, H | 1 |
März, W | 1 |
Collins, PD | 1 |
Sattar, N | 1 |
Nichols, GA | 1 |
Reynolds, K | 1 |
Olufade, T | 1 |
Kimes, TM | 1 |
O'Keeffe-Rosetti, M | 1 |
Sapp, DS | 1 |
Anzalone, D | 1 |
Fortmann, SP | 1 |
Ballantyne, CM | 2 |
Shah, S | 2 |
Kher, U | 1 |
Hunter, JA | 1 |
Gill, GG | 1 |
Cressman, MD | 1 |
Ashraf, TB | 1 |
Johnson-Levonas, AO | 1 |
Mitchel, YB | 2 |
Felts, AS | 1 |
Sanford, M | 1 |
Curran, MP | 1 |
Maccubbin, D | 2 |
Bays, HE | 1 |
Olsson, AG | 2 |
Elinoff, V | 1 |
Elis, A | 1 |
Mitchel, Y | 1 |
Sirah, W | 1 |
Betteridge, A | 1 |
Reyes, R | 1 |
Yu, Q | 1 |
Kuznetsova, O | 1 |
Sisk, CM | 1 |
Pasternak, RC | 2 |
Paolini, JF | 2 |
Jokubaitis, LA | 5 |
Lahoz, C | 1 |
Mostaza, JM | 1 |
Lauring, B | 1 |
Dishy, V | 1 |
Luo, WL | 1 |
Laterza, O | 1 |
Patterson, J | 1 |
Cote, J | 1 |
Chao, A | 1 |
Larson, P | 1 |
Gutierrez, M | 1 |
Wagner, JA | 1 |
Lai, E | 1 |
Stefanutti, C | 1 |
Mazza, F | 1 |
Vivenzio, A | 1 |
Di Giacomo, S | 1 |
Perrone, G | 1 |
Serra, M | 1 |
Bucci, A | 1 |
Parhofer, KG | 1 |
Mitka, M | 1 |
Ahmed, MH | 1 |
Ascaso, JF | 1 |
Toutouzas, K | 1 |
Drakopoulou, M | 1 |
Skoumas, I | 1 |
Stefanadis, C | 1 |
Ceska, R | 1 |
Gil-Extremera, B | 1 |
Giezek, H | 1 |
Vandormael, K | 1 |
Mao, A | 1 |
McCrary Sisk, C | 1 |
Gupta, A | 1 |
Guyomard, V | 1 |
Zaman, MJ | 1 |
Rehman, HU | 1 |
Myint, PK | 1 |
Lee, T | 1 |
Doggrell, SA | 1 |
Klose, G | 1 |
Custodis, F | 1 |
Laufs, U | 1 |
Markel, A | 1 |
Maningat, P | 1 |
Breslow, JL | 1 |
Einecke, D | 1 |
Nicholls, SJ | 1 |
Michos, ED | 1 |
Sibley, CT | 1 |
Baer, JT | 1 |
Blaha, MJ | 1 |
Blumenthal, RS | 1 |
Hamoud, S | 1 |
Kaplan, M | 1 |
Meilin, E | 1 |
Hassan, A | 1 |
Torgovicky, R | 1 |
Cohen, R | 1 |
Hayek, T | 1 |
Dänschel, W | 1 |
Steinhagen-Thiessen, E | 2 |
Buffleben, C | 1 |
Pittrow, D | 1 |
Hildemann, SK | 1 |
Packard, C | 1 |
Koeller, J | 1 |
Talbert, RL | 1 |
Nagai, Y | 1 |
Yanagi, K | 1 |
Yamashita, S | 1 |
Takemura, K | 1 |
Matsuzawa, Y | 1 |
Spirn, MJ | 1 |
Warren, FA | 1 |
Guyer, DR | 1 |
Klancnik, JM | 1 |
Spaide, RF | 1 |
Kastelein, J | 1 |
Parra, JL | 1 |
Reddy, KR | 1 |
PARSONS, WB | 7 |
ACHOR, RW | 7 |
BERGE, KG | 7 |
MCKENZIE, BF | 2 |
BARKER, NW | 3 |
O'REILLY, PO | 1 |
EILERSEN, P | 1 |
HOBOLTH, N | 1 |
RIVIN, AU | 2 |
ALTSCHUL, R | 3 |
SMART, TA | 1 |
CHRISTENSEN, NA | 3 |
MASON, HL | 3 |
KLOSTER, JH | 1 |
LJUNGGREN, H | 1 |
GRISSLER, J | 1 |
PROBST, F | 1 |
HOFFER, A | 1 |
POWER, MH | 1 |
GOLDNER, MG | 1 |
DOAK, PB | 1 |
NICHOLSON, GI | 1 |
NORTH, JD | 1 |
HEYDEN, S | 1 |
FUMAROLA, D | 1 |
GIORDANO, D | 1 |
DE RINALDIS, P | 1 |
BARNETT, AJ | 1 |
CARSON, VJ | 1 |
TRIBIANO, CW | 1 |
SPENCER, JL | 1 |
ZANETTI, ME | 1 |
TENNENT, DM | 1 |
ZELVELDER, WG | 1 |
ZWEIFLER, AJ | 1 |
HOOBLER, SW | 1 |
BOOTSMA, BK | 1 |
BURSTEIN, J | 1 |
WIRKBERG, G | 1 |
KESTERMANN, E | 1 |
PAULI, H | 1 |
KIMMERLING, HW | 1 |
VASKO, J | 1 |
YOUNGER, R | 1 |
STEPHENSON, SE | 1 |
NAVA-RIVERA, A | 2 |
RODRIGUEZ-TRUJILLO, F | 1 |
BERNALDIAZ, L | 1 |
FITZGERALD, O | 1 |
HEFFERNAN, A | 1 |
BRENNAN, P | 1 |
MULCAHY, R | 1 |
FENNELLY, JJ | 1 |
MCFARLANE, R | 1 |
TROMOVITCH, TA | 1 |
JACOBS, PH | 1 |
KERN, S | 1 |
ARTEAGA, A | 1 |
DIAZ, F | 1 |
TORRES, MC | 2 |
NUNEZ, I | 2 |
LANGE, K | 1 |
MAHL, M | 1 |
MARKIEWICZ, M | 1 |
FAIVRE, G | 1 |
GILGENKRANTZ, JM | 1 |
CHERRIER, F | 1 |
HENRY, C | 1 |
SCHOEN, H | 2 |
ZELLER, W | 1 |
HENNING, N | 1 |
MOSELEY, V | 1 |
FINCH, JW | 1 |
ARTEAGALLONA, A | 1 |
DIAZGREZ, F | 1 |
BLANKENHORN, DH | 2 |
CHIN, HP | 1 |
KLEBANOV, BM | 1 |
OWEN, WR | 1 |
KLEIN, L | 1 |
MENESESHOYOS, J | 1 |
STUETTGEN, G | 1 |
LEUTIGER, H | 1 |
GOLDSMITH, GA | 1 |
WENNERBY, S | 1 |
ROE, DA | 1 |
LIPTON, P | 1 |
MICHELS, JG | 1 |
BRANDEL, E | 1 |
MIALE, JP | 1 |
KOTTKE, BA | 1 |
BOLLMAN, JL | 1 |
JUERGENS, JL | 1 |
WILLIAMS, B | 1 |
URUCHURTU, G | 1 |
Camenga, D | 1 |
Gill, JM | 1 |
Insull, W | 1 |
McGovern, ME | 2 |
Schrott, H | 1 |
Thompson, P | 1 |
Crouse, JR | 1 |
Zieve, F | 1 |
Corbelli, J | 1 |
Jones, PH | 1 |
Schuster, H | 1 |
Superko, HR | 3 |
Raul, E | 1 |
Garrett, B | 1 |
Allegri, G | 1 |
Ragazzi, E | 1 |
Costa, CV | 1 |
Caparrotta, L | 1 |
Biasiolo, M | 1 |
Comai, S | 1 |
Bertazzo, A | 1 |
Charlotte, N | 1 |
Sani, M | 1 |
Carlson, LA | 1 |
Dunbar, RL | 1 |
Rader, DJ | 1 |
Cicero, AF | 1 |
Brancaleoni, M | 1 |
Laghi, L | 1 |
Donati, F | 1 |
Mino, M | 1 |
Zambon, A | 1 |
Brown, BG | 2 |
Hokanson, JE | 2 |
Motulsky, AG | 1 |
Brunzell, JD | 1 |
Vogt, A | 1 |
Kassner, U | 1 |
Hostalek, U | 1 |
Peiter, A | 1 |
Zhao, SP | 3 |
Yang, J | 3 |
Li, J | 3 |
Dong, SZ | 3 |
Wu, ZH | 2 |
Zhou, HN | 1 |
Abdel-Maksoud, M | 1 |
Sazonov, V | 1 |
Gutkin, SW | 1 |
Davidson, MH | 2 |
McKenney, J | 1 |
Keller, LH | 1 |
Bajorunas, DR | 1 |
Karas, RH | 1 |
Criscuoli, M | 1 |
Renzetti, AR | 1 |
Subissi, A | 1 |
Stamler, J | 1 |
Smith, SR | 1 |
Glueck, CJ | 1 |
Kane, JP | 3 |
Malloy, MJ | 2 |
Ginsberg, HN | 1 |
Oster, G | 2 |
Borok, GM | 2 |
Menzin, J | 2 |
Heys, JF | 1 |
Epstein, RS | 2 |
Quinn, V | 2 |
Benson, VV | 1 |
Dudl, RJ | 2 |
Epstein, A | 1 |
Jacobson, TA | 5 |
Amorosa, LF | 3 |
Chin, MM | 1 |
Fromell, GJ | 1 |
Probstfield, JL | 1 |
Hunninghake, DB | 2 |
Illingworth, DR | 2 |
Stein, EA | 2 |
Dujovne, CA | 1 |
Frost, PH | 1 |
Knopp, RH | 3 |
Tun, P | 1 |
Zupkis, RV | 1 |
Greguski, RA | 1 |
Stewart, BF | 1 |
Hillger, LA | 1 |
Sniderman, AD | 1 |
Dowdy, A | 1 |
Fisher, LD | 1 |
Albers, JJ | 1 |
Paterson, RW | 1 |
Paat, JJ | 1 |
Steele, GH | 1 |
Hathaway, SC | 1 |
Wong, JG | 1 |
Schectman, G | 5 |
Hiatt, J | 5 |
Hartz, A | 2 |
Smith, HT | 1 |
Troendle, AJ | 1 |
Hwang, DS | 1 |
Robinson, WT | 1 |
McKenney, JM | 3 |
Proctor, JD | 1 |
Harris, S | 1 |
Chinchili, VM | 1 |
Lasagna, L | 1 |
Luria, MH | 1 |
Sapoznikov, D | 1 |
Heudebert, GR | 1 |
Van Ruiswyk, J | 1 |
Schwartz, ML | 1 |
Lawrence, SP | 1 |
Colletti, RB | 1 |
Neufeld, EJ | 1 |
Roff, NK | 1 |
McAuliffe, TL | 1 |
Baker, AL | 1 |
Newburger, JW | 1 |
Heyse, JF | 1 |
Benson, V | 1 |
Epstein, AM | 1 |
Gorshkova, IN | 1 |
Kiseleva, NG | 1 |
Akhmedzhanov, NM | 1 |
Perova, NV | 1 |
Farmer, JA | 1 |
Gotto, AM | 2 |
Gardner, SF | 1 |
Marx, MA | 1 |
White, LM | 1 |
Skelton, DR | 1 |
Fonseca, VA | 1 |
Preobrazhenskiĭ, VN | 1 |
Matveev, AA | 1 |
Grundy, SM | 2 |
Callanan, D | 1 |
Blodi, BA | 1 |
Martin, DF | 1 |
Sikand, G | 1 |
Kashyap, ML | 1 |
Yang, I | 1 |
Guyton, JR | 2 |
Goldberg, AC | 3 |
Kreisberg, RA | 2 |
Sprecher, DL | 1 |
O'Connor, CM | 1 |
Capuzzi, DM | 2 |
Morgan, JM | 2 |
Brusco, OA | 2 |
Brody, J | 1 |
Scheen, AJ | 1 |
Gordon, BR | 1 |
Saal, SD | 1 |
Arntz, HR | 1 |
Wunderlich, W | 1 |
Schnitzer, L | 1 |
Stern, R | 1 |
Fischer, F | 1 |
Agrawal, R | 1 |
Linderer, T | 1 |
Schultheiss, HP | 1 |
Mack, WJ | 2 |
LaBree, L | 1 |
Liu, C | 1 |
Selzer, RH | 1 |
Hodis, HN | 1 |
Lee, TH | 1 |
Intenzo, CM | 1 |
Chin-Dusting, JP | 1 |
Shaw, JA | 1 |
Preuss, HG | 1 |
Wallerstedt, D | 1 |
Talpur, N | 1 |
Tutuncuoglu, SO | 1 |
Echard, B | 1 |
Myers, A | 1 |
Bui, M | 1 |
Bagchi, D | 1 |
Maki, KC | 1 |
Karp, SK | 1 |
Ingram, KA | 1 |
Jaconello, P | 1 |
Mattiussi, AJ | 1 |
Blais, D | 1 |
Prihoda, JS | 1 |
Walter, AA | 1 |
Florkowski, CM | 1 |
Cramb, R | 1 |
Krauss, RM | 1 |
Keenan, JM | 2 |
Bae, CY | 1 |
Fontaine, PL | 2 |
Wenz, JB | 2 |
Myers, S | 2 |
Huang, ZQ | 2 |
Ripsin, C | 1 |
Morrow, JD | 1 |
Prakash, C | 1 |
Duckworth, TA | 1 |
Zackert, WE | 1 |
Blair, IA | 1 |
Oates, JA | 1 |
Roberts, LJ | 1 |
Appeltauer, LC | 1 |
Gorrell, RL | 1 |
Retzlaff, BM | 1 |
Dowdy, AA | 1 |
Walden, CE | 1 |
McCann, BS | 1 |
Gey, G | 1 |
Cooper, M | 1 |
Kolman, BS | 1 |
Schwab, RA | 1 |
Bachhuber, BH | 1 |
Ripsin, CM | 1 |
Schulman, KA | 1 |
Kinosian, B | 1 |
Glick, H | 1 |
Willian, MK | 1 |
Koffer, H | 1 |
Eisenberg, JM | 1 |
Kelley, MD | 1 |
Cashin-Hemphill, L | 1 |
Pogoda, JM | 1 |
Sanmarco, ME | 1 |
Azen, SP | 1 |
Uzark, K | 1 |
Crowley, D | 1 |
Callow, L | 1 |
Bove, E | 1 |
Becker, G | 1 |
Hutchinson, RG | 1 |
Goldberg, IJ | 1 |
Holleran, S | 1 |
Ramakrishnan, R | 1 |
Adams, M | 1 |
Palmer, RH | 1 |
Dell, RB | 1 |
Goodman, DS | 1 |
Stoy, DB | 1 |
Mullin, GE | 1 |
Greenson, JK | 1 |
Mitchell, MC | 1 |
Witztum, JL | 1 |
Ose, L | 1 |
Blomhoff, JP | 1 |
Torsvik, H | 1 |
Guarini, G | 1 |
Costa, C | 1 |
Trimarco, C | 1 |
Santese, D | 1 |
Vitaliano, E | 1 |
Lueg, MC | 1 |
Anding, RH | 1 |
Smith, DA | 1 |
Karmally, W | 1 |
Brown, WV | 1 |
Urberg, M | 1 |
Benyi, J | 1 |
John, R | 1 |
Cohen, L | 1 |
Morgan, J | 1 |
Lamkin, GE | 1 |
Bewley, DZ | 1 |
Tikkanen, MJ | 1 |
Nikkilä, EA | 1 |
Havel, RJ | 1 |
Jacobsson, L | 1 |
Hoeg, JM | 1 |
Maher, MB | 1 |
Bailey, KR | 1 |
Brewer, HB | 1 |
Stuyt, PM | 1 |
Clementz, GL | 1 |
Holmes, AW | 1 |
Lynn, MD | 1 |
Gross, MD | 1 |
Shapiro, B | 1 |
Bassett, D | 1 |
Postnikova, NV | 1 |
Vasilenko, IuK | 1 |
Cherevatyĭ, VS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
Efficacy of Red Yeast Rice Based Nutraceutical (Monacolin K 10 mg/Dose) Plus Probiotic (Bifidobacterium Longum BB536 ®) in Patients With Moderate Hypercholesterolemia.[NCT02689934] | 33 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630] | Phase 3 | 25,673 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients Wit[NCT01717300] | Phase 3 | 459 participants (Actual) | Interventional | 2012-11-06 | Completed | ||
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204] | Phase 3 | 1,620 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia[NCT00769132] | Phase 1 | 26 participants (Actual) | Interventional | 2007-08-03 | Completed | ||
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes[NCT00618995] | Phase 1 | 26 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.[NCT00479388] | Phase 3 | 1,216 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
Familial Atherosclerosis Treatment Study[NCT00000512] | Phase 3 | 146 participants (Actual) | Interventional | 1984-01-31 | Completed | ||
A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects[NCT00046267] | 30 participants | Interventional | Completed | ||||
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST[NCT00082251] | Phase 3 | 0 participants | Interventional | Completed | |||
HDL Increased Plaque Stabilization in the Elderly[NCT00127218] | Phase 3 | 145 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)[NCT00005433] | 188 participants (Actual) | Observational | 1996-04-30 | Completed | |||
[NCT00000599] | Phase 3 | 0 participants | Interventional | 1980-06-30 | Completed | ||
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657] | Phase 4 | 400 participants (Anticipated) | Interventional | 2006-11-30 | Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
Intervention | participants (Number) |
---|---|
ER Niacin/Laropiprant | 807 |
Placebo | 897 |
Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
Intervention | participants (Number) |
---|---|
ER Niacin/Laropiprant | 668 |
Placebo | 694 |
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
Intervention | participants (Number) |
---|---|
ER Niacin/Laropiprant | 1696 |
Placebo | 1758 |
All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
Intervention | participants (Number) |
---|---|
ER Niacin/Laropiprant | 798 |
Placebo | 732 |
Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
Intervention | participants (Number) |
---|---|
ER Niacin/Laropiprant | 498 |
Placebo | 499 |
The creatinine-normalized urine levels of PGI-M in the overall 24 hour collection interval following administration on Day 7. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.
Intervention | pg/mg creatinine (Least Squares Mean) |
---|---|
ER Niacin 2 g / Laropiprant 40 mg | 73.5 |
ER Niacin 2 g | 70.9 |
Laropiprant 40 mg | 114.5 |
Placebo | 127.5 |
The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.
Intervention | pg/mg creatinine (Least Squares Mean) |
---|---|
ER Niacin 2 g / Laropiprant 40 mg | 414.6 |
ER Niacin 2 g | 371.6 |
Laropiprant 40 mg | 407.3 |
Placebo | 466.1 |
PGI-M in the Overall 24 Hour Collection Interval Following Administration on Day 7 (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.
Intervention | pg/mg creatinine (Least Squares Mean) |
---|---|
ER Niacin/Laropiprant | 90.1 |
ER Niacin | 95.4 |
Laropiprant | 158.5 |
Placebo | 168.1 |
The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.
Intervention | pg/mg creatinine (Least Squares Mean) |
---|---|
ER Niacin/Laropiprant | 525.3 |
ER Niacin | 540.8 |
Laropiprant | 585.3 |
Placebo | 625.1 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
Intervention | Percent (Least Squares Mean) |
---|---|
ER Niacin/Laropiprant + Run-in Statin | 15.8 |
Run-in Statin Dose Doubled | 0.2 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
Intervention | Percent (Least Squares Mean) |
---|---|
ER Niacin/Laropiprant + Run-in Statin | -10.0 |
Run-in Statin Dose Doubled | -5.5 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
Intervention | Percent (Median) |
---|---|
ER Niacin/Laropiprant + Run-in Statin | -17.6 |
Run-in Statin Dose Doubled | -4.0 |
The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries. (NCT00127218)
Timeframe: 18 months
Intervention | percentage of internal carotid artery (Mean) |
---|---|
Niacin Plus Statin | 7 |
Placebo Plus Statin | 5 |
Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded (NCT00127218)
Timeframe: 18 months
Intervention | Participants (Count of Participants) |
---|---|
Any Statin Plus Niacin | 6 |
Any Statin Plus Placebo | 2 |
52 reviews available for niacin and Elevated Cholesterol
Article | Year |
---|---|
Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
Topics: Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hy | 2021 |
Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Topics: Antibodies, Monoclonal; Biomarkers; Cholesterol, LDL; Ezetimibe; Fibric Acids; Gene Silencing; Human | 2017 |
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa | 2019 |
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Diseas | 2014 |
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reduc | 2016 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabeti | 2016 |
Niacin extended-release/simvastatin.
Topics: Animals; Clinical Trials as Topic; Drug Combinations; Flushing; Humans; Hydroxymethylglutaryl-CoA Re | 2008 |
[HDL-cholesterol: from risk factor to therapeutic target].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypercholesterolemia; Niacin; Ris | 2009 |
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Topics: Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Flushing; Humans; | 2009 |
[Advances in cholesterol-lowering interventions].
Topics: Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterole | 2010 |
Advancing therapy for hypercholesterolemia.
Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins | 2010 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combinat | 2010 |
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; D | 2011 |
[Hypertricglyceridemia: prognostic impact and treatment options].
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, R | 2011 |
The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
Topics: Cholesterol; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hypolipidemic Agents; I | 2011 |
Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou
Topics: Aged; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up | 2012 |
Management of hypercholesterolaemia in the patient with diabetes.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T | 2002 |
Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-C | 2002 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy | 1994 |
What future for combination therapies?
Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp | 2003 |
Hepatotoxicity of hypolipidemic drugs.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; F | 2003 |
[DRUGS LOWERING THE CHOLESTEROL LEVEL IN THE BLOOD].
Topics: Antimetabolites; Arteriosclerosis; Ascorbic Acid; Cholesterol; Choline; Corrinoids; Ethyl Biscoumace | 1963 |
THE INTERRELATIONS BETWEEN CHOLESTEROL AND OTHER LIPIDS. II. A REVIEW.
Topics: Arteriosclerosis; Cholesterol; Edetic Acid; Estrogens; Fats, Unsaturated; Heparin; Humans; Hyperchol | 1964 |
EFFICACY OF DRUGS IN LOWERING BLOOD CHOLESTEROL.
Topics: Cholesterol; Diet; Diet Therapy; Estrogens; Estrogens, Conjugated (USP); Fats, Unsaturated; Humans; | 1964 |
CUTANEOUS EFFECTS OF HYPOCHOLESTEREMIC AGENTS.
Topics: Anticholesteremic Agents; Drug Eruptions; Hypercholesterolemia; Ion Exchange Resins; Ketones; Niacin | 1964 |
Improving lipid management--to titrate, combine or switch.
Topics: Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Red | 2004 |
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
Topics: Adipose Tissue; Arteriosclerosis; Coronary Disease; Fatty Acids, Nonesterified; Fibrinolysis; Flushi | 2005 |
Demystifying triglycerides: a practical approach for the clinician.
Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2005 |
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Humans | 2008 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1982 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hyper | 1982 |
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Topics: Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Coronary Disease; Drug Therapy, Combinat | 1995 |
Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications.
Topics: Angiography; Clinical Trials as Topic; Colestipol; Coronary Disease; Humans; Hypercholesterolemia; L | 1994 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru | 1996 |
Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1996 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Nia | 1997 |
Niacin dosing: relationship to benefits and adverse effects.
Topics: Anticholesteremic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyper | 2000 |
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA | 2001 |
Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
Topics: Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperl | 2001 |
Lipid management: tools for getting to the goal.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Drug Therapy, Combination; Humans; Hype | 2001 |
Management of hypercholesterolaemia in postmenopausal women.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diet; Drug The | 2002 |
Drug therapy of hyperlipidemia.
Topics: Anticholesteremic Agents; Butyrates; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; | 1992 |
Therapeutic intervention for hypercholesterolemia.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Life Style; Niacin | 1992 |
Approaches to the management of hypercholesterolaemia.
Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperchol | 1992 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit A | 1990 |
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
Current approaches to drug therapy for the hypercholesterolemic patient.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-C | 1989 |
New approaches to cholesterol lowering: efficacy and safety.
Topics: Anticholesteremic Agents; Cholesterol; Dietary Fats; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Re | 1988 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 1988 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
37 trials available for niacin and Elevated Cholesterol
Article | Year |
---|---|
Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.
Topics: Adult; Bifidobacterium longum; Biological Products; Cardiovascular Diseases; Dietary Supplements; Do | 2019 |
Effects of extended-release niacin with laropiprant in high-risk patients.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin | 2014 |
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, | 2017 |
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Drug C | 2008 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru | 1994 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups.
Topics: Administration, Oral; Body Mass Index; Diet; Female; Humans; Hypercholesterolemia; Hypolipidemic Age | 2009 |
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dos | 2010 |
Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol.
Topics: Apolipoprotein A-I; C-Reactive Protein; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Hypo | 2013 |
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
Topics: Age Factors; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Disease | 2013 |
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
Topics: Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2004 |
Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
Topics: Adult; Aged; Delayed-Action Preparations; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents | 2004 |
Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study.
Topics: Adult; Aged; Anticholesteremic Agents; Capsules; Cardiovascular Diseases; Dietary Supplements; Fatty | 2005 |
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis; | 2006 |
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Topics: Administration, Oral; Adult; Aged; Cholesterol, HDL; Delayed-Action Preparations; Dose-Response Rela | 2008 |
Pharmacological trials: primary and secondary prevention of coronary heart disease.
Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D | 1983 |
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Fol | 1995 |
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy.
Topics: Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturat | 1994 |
Fluvastatin with and without niacin for hypercholesterolemia.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Cholestero | 1994 |
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Topics: Adult; Aged; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Ag | 1994 |
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Colestip | 1994 |
Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy.
Topics: Allied Health Personnel; Anticholesteremic Agents; Female; Hospitals, Veterans; Humans; Hypercholest | 1994 |
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Drug Therapy, Combination; Fatty Acids, | 1994 |
Pharmacokinetics of fluvastatin and specific drug interactions.
Topics: Adolescent; Adult; Aged; Aging; Biological Availability; Cholestyramine Resin; Diet; Digoxin; Dose-R | 1993 |
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
Topics: Adult; Capsules; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Metho | 1994 |
Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice.
Topics: Adult; Aged; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hum | 1996 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru | 1996 |
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; D | 1997 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1998 |
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hypercho | 1998 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol | 1999 |
Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography.
Topics: Adult; Carotid Artery, Common; Carotid Stenosis; Colestipol; Coronary Angiography; Coronary Artery D | 2000 |
Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study.
Topics: Analysis of Variance; Anthocyanins; Antioxidants; Blood Pressure; Cholesterol; Cholesterol, HDL; Cho | 2000 |
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin.
Topics: Adult; Aged; Aging; Alkaline Phosphatase; Blood Glucose; Delayed-Action Preparations; Double-Blind M | 1992 |
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia.
Topics: Adult; Aged; Chemistry, Pharmaceutical; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholest | 1991 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
[Effects on lipid metabolism of inhibitors of cholesterol synthesis].
Topics: Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Double-Blind Meth | 1988 |
153 other studies available for niacin and Elevated Cholesterol
Article | Year |
---|---|
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol; Cholesterol, HDL; Hypercholesterolemia; Hypolip | 1989 |
Do patients on statins also need niacin?
Topics: Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl- | 2013 |
Statin therapy: when to think twice.
Topics: Cardiovascular Diseases; Contraindications; Drug Therapy, Combination; Heart Failure; Humans; Hydrox | 2013 |
Niacin and HDL cholesterol--time to face facts.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin: old habits die hard.
Topics: Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyp | 2016 |
[Residual risk: The roles of triglycerides and high density lipoproteins].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Fibric Acids | 2016 |
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, | 2017 |
[Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
Topics: Cerebral Infarction; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; H | 2008 |
Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypercholesterolemia; Indoles; N | 2008 |
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; C | 2010 |
Ezetimibe and recent clinical trials: a look on the bright side.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed- | 2010 |
Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Topics: Drug Combinations; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Preg | 2010 |
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol?
Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxyme | 2010 |
[Optimal lipid treatment: possibilities and current limitations].
Topics: Anion Exchange Resins; Anticholesteremic Agents; Blood Component Removal; Cardiovascular Diseases; C | 2011 |
Needed: pragmatic clinical trials for statin-intolerant patients.
Topics: Clinical Trials as Topic; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2011 |
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Topics: Acute Coronary Syndrome; Amides; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, | 2011 |
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?
Topics: Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholes | 2012 |
Side effects. Niacin for cholesterol and weight problems?
Topics: Antiretroviral Therapy, Highly Active; Humans; Hypercholesterolemia; Lipodystrophy; Niacin; Triglyce | 2000 |
Optical coherence tomography findings in nicotinic acid maculopathy.
Topics: Aged; Fluorescein Angiography; Humans; Hypercholesterolemia; Hypolipidemic Agents; Interferometry; L | 2003 |
Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations.
Topics: Blood; Cholesterol; Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids | 1956 |
Some clinical aspects of nicotinic acid therapy in hypercholesterolaemia.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1958 |
Treatment of hypercholesterolemia with nicotinic acid.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1958 |
Treatment of hypercholesteremia with large oral doses of nicotinic acid: further investigations.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1958 |
USE OF nicotinic acid in hypercholesteremia.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1958 |
[Treatment of hypercholesteremia with nicotinic acid].
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1959 |
Jaundice occurring during nicotinic acid therapy for hypercholesteremia.
Topics: Cholesterol; Hypercholesterolemia; Jaundice; Niacin; Nicotinic Acids | 1959 |
Influence of nicotinic acid on starvation hypercholesteremia in rabbits.
Topics: Animals; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Rabbits; Star | 1961 |
Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice.
Topics: Cholesterol; Hypercholesterolemia; Jaundice; Niacin; Nicotinic Acids | 1961 |
Studies of nicotinic acid use in hypercholesteremia. Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism.
Topics: Carbohydrates; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Uric Acid | 1961 |
Treatment of hypercholesteremia by nicotinic acid. Progress report with review of studies regarding mechanism of action.
Topics: Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Research Report | 1961 |
[Long-term treatment of hypercholesterolemia with nicotinic acid].
Topics: Cholesterol; Humans; Hypercholesterolemia; Long-Term Care; Niacin; Nicotinic Acids | 1961 |
[Nicotinic acid treatment in hypercholesterolemia and atheromatosis].
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids | 1961 |
The effect of nicotinic acid on hypercholesterolaemia.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1960 |
Comparison of the treatment of hypercholesteremia with nicotinic acid, sitosterol, and safflower oil.
Topics: Arachidonic Acid; Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Safflower Oil; | 1959 |
[On nicotinic acid therapy of hypercholesterolemia].
Topics: Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids | 1960 |
Triparanol and nicotinic acid in the management of hypercholesterolaemia.
Topics: Anticholesteremic Agents; Cardiotonic Agents; Cholesterol; Coronary Disease; Disease Management; Hyp | 1962 |
Pharmacologic agents and lipid metabolism.
Topics: Alcohols; Heparin; Hypercholesterolemia; Lipid Metabolism; Niacin; Nicotinic Acids; Thyroxine | 1963 |
Use of nicotinic acid to reduce serum cholesterol and remove tissue cholesterol.
Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1963 |
Use of nicotinic acid to reduce serum lipid levels.
Topics: Aluminum; Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids | 1962 |
[Contribution to preventive cardiology].
Topics: Coronary Disease; Diet; Fats, Unsaturated; Heparin; Hypercholesterolemia; Ion Exchange Resins; Neomy | 1963 |
[Further research on the hypocholesteremic action of a higher homologue of nicotinic acid: 3-pyridineacetic acid].
Topics: Acetates; Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Pyridines; Research | 1963 |
Reduction of plasma cholesterol levels in atherosclerosis by diet and drug treatment.
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Diet Therapy; Fats; Humans; Hypercholesterolem | 1963 |
Aluminum nicotinate in the treatment of hypercholesteremia, hyperlipemia, and other elevated lipid levels.
Topics: Aluminum; Aluminum Compounds; Hypercholesterolemia; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids | 1962 |
Hormonal hypercholesterolemia in the dog: influence of niacin, niacinamide, benzmalecene, and cholestyramine resin.
Topics: Animals; Cholestyramine Resin; Dogs; Hypercholesterolemia; Ion Exchange Resins; Maleates; Niacin; Ni | 1963 |
[Report on a study of the clinical importance of nicotinic acid in the treatment of patients suffering with hypercholesterolemia].
Topics: Humans; Hypercholesterolemia; Niacin; Nicotinic Acids | 1963 |
Treatment of hypercholesterolemia with aluminum nicotinate.
Topics: Aluminum; Hypercholesterolemia; Niacin; Nicotinic Acids | 1962 |
Treatment of hypercholesteremia with triparanol and comparison with nicotinic acid.
Topics: Alcohols; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Triparanol | 1963 |
[A precis regarding the hypocholesterolemic activities of nicotinic acid and 3-pyridineacetic acid].
Topics: Acetates; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Pyridines | 1963 |
[A study of the value of nicotinic acid in the treatment of hypercholesteremia].
Topics: Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids | 1963 |
[Combined administration of triparanol and magnesium nicotinate in essential hypercholesterolemia].
Topics: Alcohols; Hypercholesterolemia; Hyperlipoproteinemia Type II; Magnesium; Niacin; Nicotinic Acids; Tr | 1962 |
[The influence of Complamine on serum cholesterol].
Topics: Cholesterol; Hypercholesterolemia; Leadership; Niacin; Nicotinic Acids; Theophylline; Xanthinol Niac | 1963 |
Concepts, theory and treatment of atherosclerosis.
Topics: Alcohols; Arteriosclerosis; Atherosclerosis; Fats, Unsaturated; Heparin; Hypercholesterolemia; Niaci | 1962 |
ANTI-ATHEROGENIC EFFECTS OF ALUMINUM NICOTINATE IN THE HYPERCHOLESTEROLEMIC CANINE.
Topics: Aluminum; Aluminum Compounds; Animals; Arteriosclerosis; Atherosclerosis; Dogs; Hypercholesterolemia | 1963 |
[HORMONAL INTERRELATIONS OF THE SALIVARY GLANDS. THE SALIVARY GLANDS AND THE THYROID. 1. PROTECTION BY SOME PYRIDINES FROM THE EFFECTS OF METHYLTHIOURACIL].
Topics: Dietary Fats; Hypercholesterolemia; Methylthiouracil; Niacin; Nicotinic Acids; Pathology; Picolines; | 1963 |
EFFECT OF NICOTINIC ACID ON ABNORMAL SERUM LIPIDS.
Topics: Child; Cholesterol; Geriatrics; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Lipids; Lip | 1964 |
ACANTHOSIS NIGRICANS-LIKE LESIONS FROM NICOTINIC ACID.
Topics: Acanthosis Nigricans; Adenocarcinoma; Diagnosis, Differential; Diethylstilbestrol; Humans; Hyperchol | 1964 |
[TRIPARANOL, L-TRIIODOTHYRONINE AND 3-PYRIDYL ACETIC ACID IN THE CONTROL OF CHOLESTEROLEMIA. A COMPARATIVE STUDY].
Topics: Acetates; Acetic Acid; Arteriosclerosis; Hypercholesterolemia; Niacin; Nicotinic Acids; Triiodothyro | 1963 |
A LONG TERM STUDY OF THE EFFECT OF NICOTINIC ACID MEDICATION ON HYPERCHOLESTEREMIA.
Topics: Acanthosis Nigricans; Arteriosclerosis; Coronary Disease; Diabetes Mellitus; Geriatrics; Humans; Hyp | 1963 |
[FAMILIAL XANTHOMATOUS HYPERCHOLESTEREMIA].
Topics: Adrenocorticotropic Hormone; Cortisone; Diagnosis, Differential; Diet; Diet Therapy; Dietary Fats; E | 1963 |
[STUDIES ON THE TREATMENT OF ENDOGENOUS HYPERLIPOPROTEINEMIA WITH BETA-PYRIDYL-CARBINOL].
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Lipoproteins; Methanol; Niacin | 1963 |
SKIN BREVITIES: VITILIGO.
Topics: Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Theophylline; Vitiligo | 1964 |
[THE USE OF DRUGS IN THE CONTROL OF CHOLESTEROLEMIA].
Topics: Arteriosclerosis; Diet; Hypercholesterolemia; Niacin; Nicotinic Acids; Thyroxine; Toxicology; Triiod | 1963 |
[THE SIGNIFICANCE OF INSUFFICIENT CLEARANCE IN ATHEROGENESIS].
Topics: Arteriosclerosis; Atherosclerosis; Dietary Fats; Glycerides; Heparin; Heparinoids; Hypercholesterole | 1963 |
MANAGEMENT OF HYPERCHOLESTEROLEMIA.
Topics: Cerebral Hemorrhage; Cholagogues and Choleretics; Coronary Disease; Diet; Diet Therapy; Hypercholest | 1964 |
[PHARMACOLOGICAL STUDIES ON THE PREPARATION "NICATOL"].
Topics: Arteriosclerosis; Blood Proteins; Cholesterol; Hypercholesterolemia; Lecithins; Lipids; Lipoproteins | 1963 |
[ATHEROSCLEROSIS AND CHOLESTEROLEMIA].
Topics: Arteriosclerosis; Atherosclerosis; Enzyme Inhibitors; Estrogens; Fats, Unsaturated; Heparin; Hyperch | 1963 |
[DRUGS AGAINST HYPERCHOLESTEROLEMIA].
Topics: Adrenal Cortex Hormones; Arteriosclerosis; Estrogens; Gonadal Steroid Hormones; Heparin; Humans; Hyp | 1964 |
[ON CHOLESTEROL MOBILIZATION IN THE TREATMENT OF XANTHOMA AND ATHEROSCLEROSIS].
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Drug Therapy; Heparin; Humans; Hypercholesterolemia; | 1963 |
HYPERCHOLESTEREMIA: EFFECTS OF TREATMENT WITH NICOTINIC ACID FOR THREE TO SEVEN YEARS.
Topics: Biomedical Research; Blood Chemical Analysis; Drug Therapy; Glucose Tolerance Test; Hypercholesterol | 1964 |
THERAPY OF HYPERCHOLESTEROLEMIA.
Topics: Diet; Diet Therapy; Drug Therapy; Hypercholesterolemia; Neomycin; Niacin; Nicotinic Acids | 1964 |
[COMPLAMINE TREATMENT OF PATIENTS WITH INCREASED SERUM CHOLESTEROL VALUES].
Topics: Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Niacin; Nicotinic Acid | 1964 |
THE EFFECTS OF NICOTINIC ACID ON RABBIT HYPERCHOLESTEROLEMIA AND ATHEROGENESIS.
Topics: Aorta; Arteriosclerosis; Atherosclerosis; Blood Chemical Analysis; Cholesterol; Diet; Hypercholester | 1965 |
[TREATMENT OF HYPERCHOLESTEREMIA WITH COMPLAMIN (7-/2-HYDROXY-3-(N-2-HYDROXYETHYL-N-METHYLAMINO)-PROPYLTHEOPHYLLINE NICOTINATE)].
Topics: Anticholesteremic Agents; Hypercholesterolemia; Niacin; Nicotinic Acids; Theophylline; Xanthinol Nia | 1965 |
ALUMINUM NICOTINATE: A HYPOCHOLESTEREMIC AGENT.
Topics: Aluminum; Aluminum Compounds; Anticholesteremic Agents; Drug Therapy; Hypercholesterolemia; Niacin; | 1965 |
Use of aluminum nicotinate in hypercholesterolemia.
Topics: Aluminum; Aluminum Compounds; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids | 1960 |
Comparison of effect of nicotinic acid on two different types of hypercholesteremia.
Topics: Cholesterol; Hypercholesterolemia; Hypothyroidism; Niacin; Nicotinic Acids | 1962 |
[The hypocholesterolemic effect of nicotinic acid in hypercholesterolemia induced by methylthiouracil].
Topics: Hematologic Diseases; Hypercholesterolemia; Lipid Metabolism Disorders; Methylthiouracil; Niacin; Ni | 1962 |
Hypercholesterolemia. Use of niacin and niacin combinations in therapy.
Topics: Cholesterol; Depression; Estrogens; Humans; Hypercholesterolemia; Jaundice; Niacin; Xanthomatosis | 1962 |
Treatment of hypercholesterolemia in patients with diabetes at a family practice office.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Comorbidity; Cross-Sectional Studies; Delaware; Di | 2003 |
Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cholesterol, LDL; Clinical Trials as Topic; Creat | 2004 |
Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits.
Topics: Animals; Carboxy-Lyases; Hypercholesterolemia; Indoleamine-Pyrrole 2,3,-Dioxygenase; Intestine, Smal | 2004 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids | 2004 |
Lower cholesterol without statins. Options are available.
Topics: Allylamine; Azetidines; Cholesterol, LDL; Cholinergic Antagonists; Colesevelam Hydrochloride; Ezetim | 2006 |
[Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LD | 2006 |
Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits.
Topics: Adipocytes; Analysis of Variance; Animals; Anticholesteremic Agents; Biological Transport; Cholester | 2008 |
[Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits].
Topics: Adipocytes; Adiponectin; Animals; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, | 2007 |
[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits].
Topics: Adipocytes; Animals; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Hypercholesterolemia | 2007 |
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few...
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA R | 2005 |
Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids.
Topics: Animals; Aorta; Arteriosclerosis; Blood Coagulation; Cholesterol, Dietary; Dose-Response Relationshi | 1984 |
Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy.
Topics: Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1981 |
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.
Topics: Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Niacin | 1994 |
[Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia].
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Hemostasis; Humans; Hypercholesterolemia; Hyp | 1993 |
Over-the-counter niacin.
Topics: Delayed-Action Preparations; Humans; Hypercholesterolemia; Niacin; Nonprescription Drugs; Patient Co | 1994 |
Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Drug Administration Schedule; Drug Therapy, Combination; Female | 1993 |
Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity.
Topics: Aged; Algorithms; Anticholesteremic Agents; Decision Trees; Drug Costs; Drug Therapy, Combination; F | 1993 |
New guidelines for managing hypercholesterolemia. National Cholesterol Education Program.
Topics: Algorithms; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Humans; Hypercholest | 1993 |
Severe reversible hyperglycemia as a consequence of niacin therapy.
Topics: Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Niacin | 1993 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Huma | 1993 |
Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans.
Topics: Age Factors; Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Middle | 1993 |
Transient focal hepatic defects related to sustained-release niacin.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Fatty Liver; Female; Hum | 1993 |
Niacin treatment of hypercholesterolemia in children.
Topics: Adolescent; Child; Child, Preschool; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Male; N | 1993 |
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil; | 1996 |
[Effect of enduracin on the activity of a cholesterol ester transfer protein in blood plasma of people with hypercholesteremia].
Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; F | 1996 |
[Effects of enduracin on the level of cholesterol in flying personnel].
Topics: Adult; Aerospace Medicine; Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lipo | 1997 |
Macular edema associated with nicotinic acid (niacin)
Topics: Humans; Hypercholesterolemia; Macular Edema; Male; Middle Aged; Niacin | 1998 |
Medical nutrition therapy lowers serum cholesterol and saves medication costs in men with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; California; Cholesterol; Dietary Services; Health Care Costs; | 1998 |
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hypercholesterol | 1998 |
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol].
Topics: Cholesterol, HDL; Cholesterol, LDL; Exercise Therapy; Heart Diseases; Humans; Hypercholesterolemia; | 1998 |
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992.
Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Co | 1993 |
Ask the doctor: I have very high cholesterol that isn't in the target range, even with high doses of statins. I hate to take any more pills. Any advice?
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niacin | 2000 |
A new niacin. Vitamin with an HDL kick.
Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Humans; Hypercholesterolemia; Niaci | 2001 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Niacin versus niacinamide.
Topics: Humans; Hypercholesterolemia; Niacin; Niacinamide | 1992 |
Niacin versus niacinamide.
Topics: Humans; Hypercholesterolemia; Niacin; Niacinamide | 1992 |
Megavitamin and megamineral therapy in childhood.
Topics: Flushing; Humans; Hypercholesterolemia; Niacin; Niacinamide | 1992 |
Differential effects of nicotinic acid in subjects with different LDL subclass patterns.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterole | 1992 |
A stable isotope dilution mass spectrometric assay for the major urinary metabolite of PGD2.
Topics: Asthma; Bronchoalveolar Lavage Fluid; Histamine; Humans; Hydroxyprostaglandin Dehydrogenases; Hyperc | 1991 |
Megavitamin and megamineral therapy in childhood.
Topics: Acanthosis Nigricans; Humans; Hypercholesterolemia; Niacin; Orthomolecular Therapy | 1991 |
Niacin caution.
Topics: Humans; Hypercholesterolemia; Niacin | 1991 |
Changes in vitamin and mineral intakes and serum concentrations among free-living men on cholesterol-lowering diets: the Dietary Alternatives Study.
Topics: Ascorbic Acid; beta Carotene; Carotenoids; Diet; Dietary Fats; Energy Intake; Folic Acid; Humans; Hy | 1991 |
Unstable myocardial ischemia after the initiation of niacin therapy.
Topics: Aged; Angina Pectoris; Angina, Unstable; Cholesterol, HDL; Coronary Disease; Electrocardiography; Hu | 1991 |
Delirium and lactic acidosis caused by ethanol and niacin coingestion.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Adult; Alcoholic Intoxication; Delirium; Humans; Hyperchole | 1991 |
Hypercholesterolemia: the cost of treatment in perspective.
Topics: Adult; Aged; Child; Cost-Benefit Analysis; Dietary Fiber; Electrocardiography; Evaluation Studies as | 1990 |
Hypercholesterolemia after cardiac transplantation in children.
Topics: Adolescent; Child; Child, Preschool; Female; Heart Transplantation; Humans; Hypercholesterolemia; In | 1990 |
Managing lipid disorders.
Topics: Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niaci | 1990 |
Nicotinic acid and hypercholesterolemia.
Topics: Drug Administration Schedule; Humans; Hypercholesterolemia; Niacin | 1990 |
Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism.
Topics: Adult; Aged; Cholesterol; Colestipol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Metabo | 1990 |
Controlling cholesterol with drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hypercholesterole | 1989 |
Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Hepatic Encephalopathy; | 1989 |
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988].
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Norway; Probuc | 1989 |
Hypercholesterolemia: new values, new strategies.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Coronary Disease; Energy Intake; Fe | 1986 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias | 1987 |
Hypocholesterolemic effects of nicotinic acid and chromium supplementation.
Topics: Cholesterol; Chromium; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Middle Aged; | 1988 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; | 1988 |
Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Fe | 1988 |
Lovastatin alone and in combination for treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Anion Exchange Resins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; F | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
[Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs].
Topics: Animals; Arteries; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Hyperlipoproteinemias; Hypol | 1986 |
Comparison of six pharmacologic regimens for hypercholesterolemia.
Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; | 1987 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi | 1987 |
Nicotinic acid-induced fulminant hepatic failure.
Topics: Chemical and Drug Induced Liver Injury; Hepatic Encephalopathy; Humans; Hypercholesterolemia; Liver | 1987 |
The influence of hypercholesterolaemia on the adrenal uptake and metabolic handling of 131I-6 beta-iodomethyl-19-norcholesterol (NP-59).
Topics: 19-Iodocholesterol; Adrenal Cortex; Animals; Bile; Cholesterol; Colestipol; Disease Models, Animal; | 1986 |
[Changes in lysozyme activity in hyperlipidemia and atherosclerosis in animals].
Topics: Adjuvants, Immunologic; Animals; Arteriosclerosis; Enzyme Activation; Hypercholesterolemia; Hyperlip | 1985 |